Can artificial intelligence be used for accurate remote scoring of the Psoriasis Area and Severity Index (PASI) in adult patients with plaque psoriasis? A Critically Appraised Topic

A 47-year-old man with chronic plaque psoriasis and type II diabetes mellitus on ustekinumab 45mg 12 weekly injections, his first biologic therapy, was switched to adalimumab 40mg alternate weeks (10/02/2020) when his Psoriasis Area and Severity Index (PASI) was 11.4 due to loss of effectiveness. Due to the COVID-19 outbreak, the U.K Prime Minister advised clinically vulnerable people, including people on immunosuppressive medication with comorbidities including diabetes, to stay home avoiding face-to-face contact (23/03/2020). We performed a Critically Appraised Topic review to understand whether it was possible to remotely assess his response to adalimumab with AI assistance.